Scalper1 News
Three weeks have made a big difference for KaloBios Pharmaceuticals (KBIO), whose stock since 2014 had fallen into a black hole amid struggles to get a single drug to the market. Meanwhile, AEterna Zentaris (AEZS) doubled Monday as it starts enrollment for a key drug trial. On Nov. 5, KaloBios Pharmaceuticals said it would cut 17 employees from its staff, a 61% reduction. On Nov. 13, the company said it would liquidate its assets and halt Scalper1 News
Scalper1 News